Amgen - AI Stock Analysis

Analysis generated November 10, 2025

Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology company that develops, manufactures, and delivers innovative human therapeutics. Established in 1980, Amgen has a strong reputation for its work in areas like oncology, nephrology, and inflammation, with a portfolio that includes highly successful products such as Neulasta, Enbrel, and Prolia. The company's extensive pipeline of investigational drugs promises continued growth and innovation in the biotech field.

Fundamental Analysis

Amgen's financials indicate a solid performance. Revenue for the last quarter stood at $9.56 billion. This is an increase of 4.25% compared to the previous quarter, which is a positive sign of growth. More impressively, compared to the same quarter last year, revenue has increased by 12.40%, suggesting healthy year-over-year growth.

The net income for the last quarter was $3.22 billion. This figure represents a remarkable increase of 124.58% compared to the previous quarter, providing significant positive growth. Furthermore, there's a year-over-year increase of 13.64% in net income, underscoring consistent profitability.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the last quarter was $5.91 billion, reflecting an increase of 63.48% compared to the quarter before it. On a year-over-year basis, EBITDA has grown by 12.14%. These figures highlight Amgen's strong operational efficiency and profitability.

The current Price-to-Earnings (P/E) ratio stands at 24.75. This value is within a normal range and neither particularly high nor low, indicating the stock is fairly valued compared to peers in the biotechnology sector.

Technical Analysis

The current stock price of Amgen is $320.20. This marks an increase of 10.36% compared to a month ago, indicating a bullish short-term trend. Over the past year, the stock has increased by 2.83%, suggesting a positive long-term trend.

The Simple Moving Average (SMA10) is currently 310.61, higher than the previous SMA10 of 308.43. This rise indicates a potential upward trend in price movement. The Relative Strength Index (RSI) is at 29.6, which is in oversold territory, signaling a potentially bullish condition as the stock could be poised for a rebound.

Alternative Data Analysis

Job postings and employee sentiment provide mixed signals about Amgen's operational strategy. The company has 1,094 open positions, down by 17% over the past couple of months, indicating potential cost-cutting measures. Employee sentiment regarding business outlook is neutral.

In terms of customer acquisition, Amgen's website has attracted 550,000 visitors, an increase of 27% in the last couple of months. This is a bullish indicator, signaling a potential rise in customer interest and engagement.

Customer engagement metrics reveal that Amgen has 32,000 followers on Instagram, with a 7% increase in recent months, showing growing interest in the company. However, its Twitter following of 120,000 has stagnated, indicating a plateau in interest from this social media platform. Overall, Amgen has an AltIndex AI score of 58, which is a hold signal.

Conclusion and Recommendation

Amgen's stock presents a mixed but predominantly positive picture. Fundamental analysis shows strong financial health with significant growth in revenue, net income, and EBITDA. From a technical perspective, the stock is in a bullish trend and may benefit from being oversold as indicated by the RSI.

However, reduced job postings suggest cost-cutting efforts, which might be a concern despite the rising customer interest. Social media metrics show a mixed engagement trend. Given the AltIndex AI score of 58, it is reasonable to maintain a neutral stance.

Overall, the recommendation based on the provided data is a Hold. The financials are robust, but investor should watch closely for further signs of operational strategy and market interest.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.